1-3 of 3
Sunil Nagpal
Close
Sort by
Journal Articles

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R

Kieron Dunleavy, MD, Ariela Noy, MD, Jeremy S. Abramson, MD, Ann S. LaCasce, MD, Brian K Link, MD, Samir Parekh, MD, Deepa Jagadeesh, MD MPH, Philip J Bierman, MD, Ronald T. Mitsuyasu, MD, Ramakrishna Battini, MD, Peter R Watson, MD, David Peace, MD, Bruce J Averbrook, MD, Harris V. Naina, MD, Joseph W Leach, MD, Wahid T Hanna, MD, Bayard L. Powell, MD, Sunil Nagpal, MD, Mark Roschewski, MD, Andrea N Lucas, RN, Seth M. Steinberg, PhD, Brad S Kahl, MD, Jonathan W. Friedberg, MD MMSc, Richard F Little, MDMPH, Nancy L Bartlett, MD, Michelle A. Fanale, MD, Wyndham H Wilson, MD PhD
Journal: Blood
Blood (2015) 126 (23): 342.
https://doi.org/10.1182/blood.V126.23.342.342
Published: 2015
Journal Articles

Hypercoagulation in Malignancy: Localized by Thromboelastography to the Humoral Phase of Coagulation

Sunil Nagpal, MD, Dianne E Schwartz, BS, Edward Faber, Andrea Cziffer, MD, Chethan Puttarajappa, MD, Dexter Toribio Estrada, MD, Kenneth A. Schwartz, MD
Journal: Blood
Blood (2008) 112 (11): 5352.
https://doi.org/10.1182/blood.V112.11.5352.5352
Published: 2008
Journal Articles

Kaposi sarcoma is a therapeutic target for vitamin D 3 receptor agonist

Clinical Trials & Observations
Rizwan Masood, Sunil Nagpal, Tong Zheng, Jie Cai, Anil Tulpule, D. Lynne Smith, Parkash S. Gill
Journal: Blood
Blood (2000) 96 (9): 3188–3194.
https://doi.org/10.1182/blood.V96.9.3188
Published: 2000